133 related articles for article (PubMed ID: 16014560)
1. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells.
Mayr C; Kofler DM; Büning H; Bund D; Hallek M; Wendtner CM
Blood; 2005 Nov; 106(9):3223-6. PubMed ID: 16014560
[TBL] [Abstract][Full Text] [Related]
2. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM
Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955
[TBL] [Abstract][Full Text] [Related]
3. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
4. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
[TBL] [Abstract][Full Text] [Related]
5. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes.
Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2007 Jun; 35(6):920-30. PubMed ID: 17533046
[TBL] [Abstract][Full Text] [Related]
6. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia.
Tolba KA; Bowers WJ; Eling DJ; Casey AE; Kipps TJ; Federoff HJ; Rosenblatt JD
Mol Ther; 2002 Oct; 6(4):455-63. PubMed ID: 12377186
[TBL] [Abstract][Full Text] [Related]
7. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
8. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Bamberger M; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2006 Jan; 34(1):44-53. PubMed ID: 16413390
[TBL] [Abstract][Full Text] [Related]
9. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
[TBL] [Abstract][Full Text] [Related]
10. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.
Pascutti MF; Jak M; Tromp JM; Derks IA; Remmerswaal EB; Thijssen R; van Attekum MH; van Bochove GG; Luijks DM; Pals ST; van Lier RA; Kater AP; van Oers MH; Eldering E
Blood; 2013 Oct; 122(17):3010-9. PubMed ID: 24014238
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Litzinger MT; Foon KA; Tsang KY; Schlom J; Palena C
Leuk Res; 2010 Oct; 34(10):1351-7. PubMed ID: 20122733
[TBL] [Abstract][Full Text] [Related]
12. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.
Wierda WG; Cantwell MJ; Woods SJ; Rassenti LZ; Prussak CE; Kipps TJ
Blood; 2000 Nov; 96(9):2917-24. PubMed ID: 11049967
[TBL] [Abstract][Full Text] [Related]
13. B-cell chronic lymphocytic leukemia-derived dendritic cells stimulate allogeneic T-cell response and express chemokines involved in T-cell migration.
Łuczyński W; Stasiak-Barmuta A; Piszcz J; Iłendo E; Kowalczuk O; Krawczuk-Rybak M
Neoplasma; 2007; 54(6):527-35. PubMed ID: 17949237
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.
Hayden RE; Pratt G; Roberts C; Drayson MT; Bunce CM
Leuk Lymphoma; 2012 Apr; 53(4):537-49. PubMed ID: 21812539
[TBL] [Abstract][Full Text] [Related]
15. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.
Biagi E; Yvon E; Dotti G; Amrolia PJ; Takahashi S; Popat U; Marini F; Andreeff M; Brenner MK; Rousseau RF
Hum Gene Ther; 2003 Apr; 14(6):545-59. PubMed ID: 12718765
[TBL] [Abstract][Full Text] [Related]
16. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade.
Pallasch CP; Ulbrich S; Brinker R; Hallek M; Uger RA; Wendtner CM
Leuk Res; 2009 Mar; 33(3):460-4. PubMed ID: 18838168
[TBL] [Abstract][Full Text] [Related]
17. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia.
Tolba KA; Bowers WJ; Hilchey SP; Halterman MW; Howard DF; Giuliano RE; Federoff HJ; Rosenblatt JD
Blood; 2001 Jul; 98(2):287-95. PubMed ID: 11435295
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.
Okur FV; Yvon E; Biagi E; Dotti G; Carrum G; Heslop H; Mims MP; Fratantoni JC; Peshwa MV; Li L; Brenner MK
Cytotherapy; 2011 Oct; 13(9):1128-39. PubMed ID: 21745159
[TBL] [Abstract][Full Text] [Related]
19. Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B cells into Ab-secreting cells.
Ghamlouch H; Ouled-Haddou H; Guyart A; Regnier A; Trudel S; Claisse JF; Fuentes V; Royer B; Marolleau JP; Gubler B
Immunol Cell Biol; 2014 Aug; 92(7):591-604. PubMed ID: 24797583
[TBL] [Abstract][Full Text] [Related]
20. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells.
Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2006 Jul; 34(7):860-9. PubMed ID: 16797413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
